What is NBP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NBP?

P/E (TTM) is n/a and 52-week range is $1.31 to $6.79 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NBP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NBP?

The company profile lists revenue (TTM) near $20M, net income (TTM) near $-9.01B, EPS (TTM) near $-0.19 when available from the market-data feed. Figures are informational and may lag live markets.

Where is NovaBridge Biosciences based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rockville, Maryland, US, 115.3M shares outstanding, ISIN US44975P1030 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

NovaBridge Biosciences

$NBP

Health Care · Biotechnology

IR Run Scenarios

$1.40

+1.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 30 full-time employees. The company went IPO on 2020-01-17. The firm combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

Employees

Website

www.novabridge.com/

IPO

2020-01-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)